ENOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Enovis Corp (ENOV) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is trading near its 52-week low amid macroeconomic pressures, and while analysts see potential upside, the company's financials remain weak with significant net income losses. The technical indicators and options data suggest a neutral to bearish sentiment, and there are no strong proprietary trading signals to support an immediate buy decision.
The stock's technical indicators show a bearish trend. The moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5), and the RSI is neutral at 39.881. The MACD histogram is slightly positive at 0.166 but contracting, indicating weak momentum. Key support is at $21.41, and resistance is at $23.259. The stock is trading near its support level, but no strong reversal signals are present.
Analysts have maintained 'Buy' ratings with price targets ranging from $40 to $50, citing confidence in the company's orthopedic strategy and improving financial profile.
Revenue grew by 8.65% YoY in Q3 2025, and gross margin improved to 52.23%.
Evercore ISI projects improved cash flow for FY26, with free cash flow conversion expected to exceed 25% in Q4.
The stock recently hit a 52-week low of $21.00, reflecting significant macroeconomic pressures.
Net income remains deeply negative at -$571.1M, despite YoY improvement.
Analysts have lowered price targets recently, and sector rotation and potential ACA/Medicare changes pose risks.
No significant insider or hedge fund activity indicates a lack of strong institutional confidence.
In Q3 2025, revenue increased by 8.65% YoY to $548.91M, and gross margin improved to 52.23%. However, net income remains significantly negative at -$571.15M, and EPS is -9.99. While these metrics show improvement YoY, the company is still far from profitability.
Analysts have a generally positive outlook, with multiple 'Buy' ratings and price targets ranging from $40 to $50. However, some firms have lowered their price targets recently, citing sector rotation and macroeconomic risks. Analysts believe the company's orthopedic strategy and improving financial profile offer long-term potential.
